GlobeNewsWire
06 Dec 2025, 14:30 UTC · 45w ago
Verdict
Headline takes no side. We score COGT +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Cogent Biosciences is on track to submit a New Drug Application (NDA) for bezuclastinib to the FDA in December 2025.
More positive than 99% of claims this week
The SUMMIT trial showed bezuclastinib achieved statistically significant improvements in both patient-reported symptoms and objective disease markers (serum tryptase, bone marrow mast cells).
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 98% of claims this week
Bezuclastinib was granted Breakthrough Therapy Designation in October 2025.
More positive than 81% of claims this week
The drug demonstrated a favorable safety and tolerability profile supporting chronic use.
More positive than 69% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company reported positive clinical trial results for bezuclastinib and is on track for an NDA submission to the FDA.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
16h ago
−19.4%
Price is moving against the score
$31.24 vs $38.77 close before publication (Dec 5) · not market-adjusted
COGT chart →
